Abstract 4129675: Effective Transcatheter Intracoronary Delivery of mRNA-Lipid Nanoparticle Targeting on The Heart

Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 150; no. Suppl_1; p. A4129675
Main Authors Handa, Kazuma, Kawamura, Masashi, Sasai, Masao, Matsuzaki, Takashi, Harada, Akima, Miki, Kenji, Fujimura, Lisa, Saito, Shunsuke, Tsuneda, Ryo, Fujishiro, Anri, Hirano, Kunio, Miyagawa, Shigeru
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 12.11.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy of transcatheter intracoronary (IC) administration compared to intravenous (IV) and intramyocardial (IM) administration as methods for delivering. Methods: Normal rabbits were used to examine each route of administration. Fluorescence (ATTO 700)-labeled LNP encapsulating Firefly Luciferase (FLuc) mRNA (25 ug/kg) were used to confirm the in vivo mRNA-LNP dynamics. The LNP accumulation and FLuc expression were verified using an in vivo imaging system (IVIS) 4 hours post-administration, followed by immunohistochemical analysis. The same experiments were conducted in an ischemia-reperfusion (I/R) model. Results: In the normal model, IVIS spectrum data showed that LNPs accumulated in the order of IM, IC and IV groups, with FLuc expression significantly higher in the IC group than in the IV group and comparable to the IM group (A). Histological analysis revealed that FLuc-expressing cells were mainly found in troponin T-positive cardiomyocytes at the injection site in the IM group and throughout the heart in the IC group (B). In the I/R model, LNP accumulation and FLuc expression were increased in the IV group compared to the normal model, whereas, in the IC and IM groups LNP accumulation and FLuc expression levels were similar to those in the normal model (C). Histological analysis revealed more FLuc-expressing cells in the infarcted area in all groups, but higher FLuc expression was observed in remote areas in the IC group (D). Conclusions: IC administration effectively delivered mRNA-LNPs not only to the damaged area but also to the remote area (non-damaged area) in the diseased heart, suggesting a safe and useful method for delivery to a wider range of cardiomyocytes in the heart.
AbstractList Abstract only Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy of transcatheter intracoronary (IC) administration compared to intravenous (IV) and intramyocardial (IM) administration as methods for delivering. Methods: Normal rabbits were used to examine each route of administration. Fluorescence (ATTO 700)-labeled LNP encapsulating Firefly Luciferase (FLuc) mRNA (25 ug/kg) were used to confirm the in vivo mRNA-LNP dynamics. The LNP accumulation and FLuc expression were verified using an in vivo imaging system (IVIS) 4 hours post-administration, followed by immunohistochemical analysis. The same experiments were conducted in an ischemia-reperfusion (I/R) model. Results: In the normal model, IVIS spectrum data showed that LNPs accumulated in the order of IM, IC and IV groups, with FLuc expression significantly higher in the IC group than in the IV group and comparable to the IM group (A). Histological analysis revealed that FLuc-expressing cells were mainly found in troponin T-positive cardiomyocytes at the injection site in the IM group and throughout the heart in the IC group (B). In the I/R model, LNP accumulation and FLuc expression were increased in the IV group compared to the normal model, whereas, in the IC and IM groups LNP accumulation and FLuc expression levels were similar to those in the normal model (C). Histological analysis revealed more FLuc-expressing cells in the infarcted area in all groups, but higher FLuc expression was observed in remote areas in the IC group (D). Conclusions: IC administration effectively delivered mRNA-LNPs not only to the damaged area but also to the remote area (non-damaged area) in the diseased heart, suggesting a safe and useful method for delivery to a wider range of cardiomyocytes in the heart.
Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy of transcatheter intracoronary (IC) administration compared to intravenous (IV) and intramyocardial (IM) administration as methods for delivering. Methods: Normal rabbits were used to examine each route of administration. Fluorescence (ATTO 700)-labeled LNP encapsulating Firefly Luciferase (FLuc) mRNA (25 ug/kg) were used to confirm the in vivo mRNA-LNP dynamics. The LNP accumulation and FLuc expression were verified using an in vivo imaging system (IVIS) 4 hours post-administration, followed by immunohistochemical analysis. The same experiments were conducted in an ischemia-reperfusion (I/R) model. Results: In the normal model, IVIS spectrum data showed that LNPs accumulated in the order of IM, IC and IV groups, with FLuc expression significantly higher in the IC group than in the IV group and comparable to the IM group (A). Histological analysis revealed that FLuc-expressing cells were mainly found in troponin T-positive cardiomyocytes at the injection site in the IM group and throughout the heart in the IC group (B). In the I/R model, LNP accumulation and FLuc expression were increased in the IV group compared to the normal model, whereas, in the IC and IM groups LNP accumulation and FLuc expression levels were similar to those in the normal model (C). Histological analysis revealed more FLuc-expressing cells in the infarcted area in all groups, but higher FLuc expression was observed in remote areas in the IC group (D). Conclusions: IC administration effectively delivered mRNA-LNPs not only to the damaged area but also to the remote area (non-damaged area) in the diseased heart, suggesting a safe and useful method for delivery to a wider range of cardiomyocytes in the heart.
Author Kawamura, Masashi
Matsuzaki, Takashi
Saito, Shunsuke
Sasai, Masao
Hirano, Kunio
Fujishiro, Anri
Handa, Kazuma
Miki, Kenji
Fujimura, Lisa
Miyagawa, Shigeru
Tsuneda, Ryo
Harada, Akima
Author_xml – sequence: 1
  givenname: Kazuma
  surname: Handa
  fullname: Handa, Kazuma
  organization: Osaka University, Osaka, Japan
– sequence: 2
  givenname: Masashi
  surname: Kawamura
  fullname: Kawamura, Masashi
  organization: Osaka University, Osaka, Japan
– sequence: 3
  givenname: Masao
  surname: Sasai
  fullname: Sasai, Masao
  organization: OSAKA UNIVERSITY, Osaka, Japan
– sequence: 4
  givenname: Takashi
  surname: Matsuzaki
  fullname: Matsuzaki, Takashi
  organization: Osaka University, Osaka, Japan
– sequence: 5
  givenname: Akima
  surname: Harada
  fullname: Harada, Akima
  organization: Osaka University, Osaka, Japan
– sequence: 6
  givenname: Kenji
  surname: Miki
  fullname: Miki, Kenji
  organization: Osaka Univerisy, Suita, Osaka, Japan
– sequence: 7
  givenname: Lisa
  surname: Fujimura
  fullname: Fujimura, Lisa
  organization: Osaka University, Osaka, Japan
– sequence: 8
  givenname: Shunsuke
  surname: Saito
  fullname: Saito, Shunsuke
  organization: Osaka University Graduate School of Medicine, Suita, Osaka, Japan
– sequence: 9
  givenname: Ryo
  surname: Tsuneda
  fullname: Tsuneda, Ryo
  organization: Terumo Corporation, Innovation Center, Kanagawa, Japan
– sequence: 10
  givenname: Anri
  surname: Fujishiro
  fullname: Fujishiro, Anri
  organization: Terumo Corporation, Innovation Center, Kanagawa, Japan
– sequence: 11
  givenname: Kunio
  surname: Hirano
  fullname: Hirano, Kunio
  organization: Terumo Corporation, Innovation Center, Kanagawa, Japan
– sequence: 12
  givenname: Shigeru
  surname: Miyagawa
  fullname: Miyagawa, Shigeru
  organization: Osaka university graduate school, Suita Osaka, Japan
BookMark eNqFkNFOwjAUhhuDiYC-Q19gs11X1hlvCKKQEEwMXjddd8amo13aIvHtLYF7r05P_v9r2m-CRsYaQAhTklI6o4-6czqlnKT-OAy9pGlOs3JW8Bs0pjzLk5yzcoTGhJAyKViW3aGJ919xnbGCj5GbVz44pQO-ck942TSgQ_cDeOeU8VqFFgI4vDbnonXWKPeLX6CPlXiwDT58bOfJphu6Gm-VsYNyodN95JXbQ-jMHluDdy3gFcToHt02qvfwcJ1T9Pm63C1Wyeb9bb2YbxJNScaTAhRnTBBglDLFMlrrQlSECKG0IKrMq7oCVnGlakoY16UQpOYFrWNR6RhNkbjcq5313kEjB9cd4tslJfLsTp7dyehOXt3Jq4OIPl_Qk-3j1_13fzyBky2oPrT_43_1R3zW
ContentType Journal Article
Copyright 2024 by American Heart Association, Inc.
Copyright_xml – notice: 2024 by American Heart Association, Inc.
DBID AAYXX
CITATION
DOI 10.1161/circ.150.suppl_1.4129675
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage A4129675
ExternalDocumentID 10_1161_circ_150_suppl_1_4129675
AHA_2023_4129675
Genre meeting-abstract
GroupedDBID ---
.-D
.3C
.XZ
.Z2
01R
0R~
0ZK
18M
1J1
29B
2FS
354
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AASXQ
AAUEB
AAWTL
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABPMR
ABQRW
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACOAL
ACRKK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADCYY
ADGGA
ADHPY
AE6
AEBDS
AENEX
AFBFQ
AFCHL
AFDTB
AFEXH
AFMBP
AFNMH
AFSOK
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
ASPBG
AVWKF
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BYPQX
C45
CS3
DIK
DIWNM
DU5
E3Z
EBS
EEVPB
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
O9-
OAG
OAH
OBH
OCB
ODMTH
OGEVE
OHH
OHYEH
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
UPT
V2I
VVN
W2D
W3M
WH7
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
YOC
YSK
YYM
YZZ
ZFV
ZY1
~H1
AAFWJ
AAYXX
ABPXF
CITATION
ID FETCH-LOGICAL-c1025-7ea53380e3113a321dc78b0088ac80a94bdbe3b5aad1035c9880d571d1dcacbe3
ISSN 0009-7322
IngestDate Thu Jul 03 08:28:00 EDT 2025
Wed Apr 16 02:26:58 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue Suppl_1
IssueTitle Abstracts From the American Heart Association's 2024 Scientific Sessions and the American Heart Association's 2024 Resuscitation Science Symposium
Keywords Coronary circulation
Nucleosides and nucleotides
Ischemia reperfusion
Drug administration
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1025-7ea53380e3113a321dc78b0088ac80a94bdbe3b5aad1035c9880d571d1dcacbe3
Notes Author Disclosures: For author disclosure information, please visit the AHA Scientific Sessions website.
ParticipantIDs crossref_primary_10_1161_circ_150_suppl_1_4129675
wolterskluwer_health_10_1161_circ_150_suppl_1_4129675
PublicationCentury 2000
PublicationDate 2024-November-12
2024-11-12
PublicationDateYYYYMMDD 2024-11-12
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-November-12
  day: 12
PublicationDecade 2020
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAbbrev Circulation
PublicationYear 2024
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
SSID ssj0006375
Score 2.4642167
Snippet Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and...
Abstract only Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an...
SourceID crossref
wolterskluwer
SourceType Index Database
Publisher
StartPage A4129675
Title Abstract 4129675: Effective Transcatheter Intracoronary Delivery of mRNA-Lipid Nanoparticle Targeting on The Heart
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1161/circ.150.suppl_1.4129675
Volume 150
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdZB2MwxtZurPtCD2MvwVlk-XNvodvIVlrYSKFvRpJlKG3tkdiU5o_q37g7SbbjktGtLyZRbCn2_XynO_10R8gHBXq_8AvhYXpzLwCb40mtQ49hcquC5_ACmmyfx9H8JPhxGp6ORjcbrKWmlhO13rqv5D5ShTaQK-6S_Q_Jdp1CA3wG-cIRJAzHf5LxTGKgQtXjAOwpzMnRvbfpiJEPZMyQScuKiRC_YxRXYb4C5Ml90RdIyLDL67-OZx7WsM5R14ITbQcaLwxJ3LCiS8PMmOtbGZEOzpbKlf_aVtVnI8owx4CFZW-sm94UHIorcdmYUkfjI7HCwk5dyAe-nrXtVR84r1fNWtha2wtx3l3hAhd-gDv4mD9QxqkXc7steaKd_oXzgtDmN-oUtE1N65Boqp1mbLv6j1D9K7j5CVwE5secOnFC6E1eu8x_yxJ2_ETjGUUsw54y6ClzPWWupwfkoQ9uCerVw599dvqIx2FbuQ9vrGWORezT3_7TYDr05KpCisTq3OyQ2JjnLJ6Rp85BoTMLgudkpMtdsjcrRV1dXtOP1FCGzVrMLnl05JgZe2TZYpG6IT_TDol0gEQ6QCJtkUirgvZIpJtIpB0SaVVSQCI1SHxBTr59XRzMPVfPw1PMVE3WApyLZKo5Y1xwn-UqTkDtJ4lQyVSkgcyl5jIUImdTHqoUbEsexiyHE4WCn16SnbIq9StCdeLzMNJaJqIIeBLKRBcanB8pY67TNN4nrH2s2W-btiW7S6j7JBw8_8zuRL7zutf3GOsNedy_Em_JTr1s9DuY3dbyvYHUH8E2pSk
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+4129675%3A+Effective+Transcatheter+Intracoronary+Delivery+of+mRNA-Lipid+Nanoparticle+Targeting+on+The+Heart&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Handa%2C+Kazuma&rft.au=Kawamura%2C+Masashi&rft.au=Sasai%2C+Masao&rft.au=Matsuzaki%2C+Takashi&rft.date=2024-11-12&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=150&rft.issue=Suppl_1&rft_id=info:doi/10.1161%2Fcirc.150.suppl_1.4129675&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_circ_150_suppl_1_4129675
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon